Article
Microbiology
James A. Karlowsky, Meredith A. Hackel, Mark G. Wise, David A. Six, Tsuyoshi Uehara, Denis M. Daigle, Susan M. Cusick, Daniel C. Pevear, Greg Moeck, Daniel F. Sahm
Summary: Taniborbactam demonstrated potent in vitro activity against Enterobacterales and P. aeruginosa, reducing cefepime MIC90 by > 64-fold and 4-fold, respectively. It inhibited a high percentage of multidrug-resistant isolates and those carrying serine carbapenemases or NDM/VIM metallo-β-lactamases. This novel combination therapy shows promise in treating infections caused by carbapenem-resistant bacteria.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2023)
Review
Immunology
Arsheena Yassin, Mariya Huralska, Jason M. Pogue, Deepali Dixit, Robert G. Sawyer, Keith S. Kaye
Summary: The prevalence of multidrug-resistant gram-negative bacterial infections has significantly increased in the past decade, leading to higher rates of morbidity and mortality. Treating these infections presents challenges, particularly for critically ill patients with limited margin for error. The availability of new therapies has improved treatment options, but optimal clinical and therapeutic approaches for managing these infections still need to be established.
CLINICAL INFECTIOUS DISEASES
(2023)
Article
Pharmacology & Pharmacy
Bela G. Santani, Brian W. LeBlanc, Ritesh P. Thakare
Summary: Cefepime/taniborbactam is a combination drug for the treatment of complicated urinary tract infections and hospital-acquired bacterial pneumonia. It has received priority approval from the FDA and is undergoing clinical trials in pediatric subjects.
DRUGS OF THE FUTURE
(2022)
Article
Microbiology
Cesar Montelongo Hernandez, Catherine Putonti, Alan J. Wolfe
Summary: This study investigates the presence of plasmids in 11 clinically relevant urinary species, identifying evidence of plasmids in some bacteria with potential virulence and antibiotic resistance genes. This research represents an initial step towards understanding the role of plasmids in the bacterial urobiota.
MICROBIOLOGY SPECTRUM
(2021)
Article
Biology
Ann A. Elshamy, Sarra E. Saleh, Mohammad Y. Alshahrani, Khaled M. Aboshanab, Mohammad M. Aboulwafa, Nadia A. Hassouna
Summary: Gram-negative bacteria are common causes of urinary tract infections (UTIs) and can exhibit resistance to carbapenems. This study found a relatively high rate of carbapenem resistance among Gram-negative bacteria causing UTIs in Cairo, Egypt, with the ability for this resistance to be horizontally transferred to other bacterial hosts.
Article
Biotechnology & Applied Microbiology
Mbarga M. J. Arsene, Podoprigora I. Viktorovna, Goriainov V. Sergei, Fadi Hajjar, Yashina N. Vyacheslavovna, Zhigunova A. Vladimirovna, Vasilyeva E. Aleksandrovna, Senyagin A. Nikolayevich, Nadezhda Sachivkina
Summary: In this study, the phytochemical composition of Aloe vera extract was investigated, and its antibacterial and antibiofilm formation activity were evaluated. The results showed that Aloe vera has significant antibacterial activity against resistant bacteria and has the potential to inhibit biofilm formation.
FERMENTATION-BASEL
(2022)
Review
Medicine, General & Internal
Branka Bedenic, Tomislav Mestrovic
Summary: Urinary tract infections are common and the pathogens causing them easily acquire various resistance determinants, including different beta-lactamases and carbapenemases. Phenotypic tests like the double-disk synergy test are used for detecting beta-lactamases, while PCR is mainly done in reference labs for resistance gene detection. The emergence of drug-resistant bacterial strains poses serious challenges in UTI management, stressing the need for tailored interventions in antimicrobial stewardship.
Article
Biochemistry & Molecular Biology
Xingpei Hao, Marcus Cognetti, Chiraag Patel, Nathalie Jean-Charles, Arun Tumati, Rhonda Burch-Smith, Mara Holton, Deepak A. Kapoor
Summary: Complicated urinary tract infections (cUTIs) are challenging to treat and resource-intensive. PCR testing is more effective than urine culture (UC) for detecting cUTIs, especially when the PCR panel size is larger.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Immunology
Jonathan Josephs-Spaulding, Thoger Jensen Krogh, Hannah Clara Rettig, Mark Lyng, Mariam Chkonia, Silvio Waschina, Simon Graspeuntner, Jan Rupp, Jakob Moller-Jensen, Christoph Kaleta
Summary: This article discusses the ecological interactions of human urogenital microbial communities, the mechanism of imbalance between microbial ecology and host physiology. A greater understanding of environmental mechanisms and microbial ecology is needed for the treatment and management of UTIs. The use of next generation and systems level methods is recommended to elucidate the systemic consequences of rUTIs.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2021)
Article
Infectious Diseases
Elkin Lemos-Luengas, Sixta Renteria-Valoyes, Paola Cardenas-Isaza, Jorge A. Ramos-Castaneda
Summary: The study aimed to analyze the in vitro antimicrobial activity of Ceftazidime/avibactam (CAZ/AVI) and other antibiotics against isolates of enterobacterales and Pseudomonas aeruginosa from patients with complicated urinary tract infection (cUTI) and complicated intra-abdominal infection (cIAI) in Colombian hospitals between 2014 and 2018. The results showed that CAZ/AVI exhibited good in vitro activity against multidrug-resistant (MDR) enterobacterales and Pseudomonas aeruginosa in patients with cUTI and cIAI.
BRAZILIAN JOURNAL OF INFECTIOUS DISEASES
(2022)
Article
Microbiology
Michael W. Dunne, Sailaja Puttagunta, Steven Aronin, Stephen Brossette, John Murray, Vikas Gupta
Summary: Resistance to oral antibiotics commonly used to treat outpatient UTIs is increasing, and almost 22% of patients were found to receive an antibiotic to which the pathogen was resistant. These patients were almost twice as likely to require a second prescription or be hospitalized within 28 days compared to those who received an antibiotic to which the pathogen was susceptible. Additionally, about 1% of Enterobacterales isolates were resistant to all commonly available classes of oral antibiotics. Age, diabetes mellitus, gender, and prior antibiotic resistance were identified as risk factors for treatment failure.
MICROBIOLOGY SPECTRUM
(2022)
Article
Medicine, General & Internal
Masayuki Maeda, Takeshi Hasegawa, Hisashi Noma, Erika Ota
Summary: This systematic review and meta-analysis aims to explore and compare the clinical outcomes of complicated urinary tract infections caused by antimicrobial-resistant uropathogens treated with carbapenem and non-carbapenem antibiotics. The study will search and assess relevant articles published until December 2022, and estimate the treatment effects using the random-effects model.
Review
Health Care Sciences & Services
Ryan Dillon, Jennifer Uyei, Rajpal Singh, Eilish McCann
Summary: The study aimed to assess the suitability of network meta-analysis (NMA) using antibacterial treatment evidence in complicated urinary tract infection. While 25 trials were reviewed with low risk of bias, the heterogeneous data and lack of key assumptions being met made it impractical and likely unreliable to use NMA for comparing novel antibacterial agents.
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH
(2021)
Article
Microbiology
David Melnick, Angela K. Talley, Vipul K. Gupta, Ian A. Critchley, Paul B. Eckburg, Kamal A. Hamed, Nivedita Bhatt, Gary Moore, Daren Austin, Christopher M. Rubino, Sujata M. Bhavnani, Paul G. Ambrose
Summary: The clinical relevance of bacteriuria after antibiotic treatment of complicated urinary tract infections is controversial. This study evaluated the impact of urine pharmacokinetics on the timing of recurrent bacteriuria in a clinical trial comparing oral tebipenem pivoxil hydrobromide and intravenous ertapenem. The prolonged urinary clearance and dwell time of ertapenem were associated with a temporal difference in the repopulation of bladder urine with bacteria following treatment, potentially confounding efficacy assessment.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2023)
Article
Immunology
Michael W. Dunne, Steven Aronin, Anita F. Das, Karthik Akinapelli, Jeanne Breen, Michael T. Zelasky, Sailaja Puttagunta
Summary: This study compared the clinical and microbiological responses of different treatment regimens in patients with complicated urinary tract infections, and the results showed that sulopenem was not superior to the comparator regimen.
CLINICAL INFECTIOUS DISEASES
(2023)
